Synta66 - Moligand™, ≥99%, used for Synta66 has been used:
as a Ca2+ release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoforms
as an ORAI1 blocker to study its effects on the entry of Ca2+ in chronic lymphocytic leukemia (CL
Synta66 - Moligand™, ≥99%, used for Synta66 has been used:
as a Ca2+ release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoforms
as an ORAI1 blocker to study its effects on the entry of Ca2+ in chronic lymphocytic leukemia (CL
GRADE & PURITYMoligand™?Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.≥99%
Moligand™, ≥99% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
🌡
Storage & shipping
Store at -20°C,Desiccated Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
📋
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
📚
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
概要
Synta66 is an inhibitor of store-operated calcium entry channel Orai , which forms the pore of the CRAC channel, and used for the research of neurological disease .
In Vitro
Synta66 is an inhibitor of Orai, which forms the pore of the CRAC channel. Synta66 (10 μM) attenuates peak SOCE in Müller glia. Synta66 (10 μM) prevents orai channels mediating the residual SOC current in Trpc1 −/− Müller cells. Synta66 (10 μM) nearly completely blocks the Ca 2+ entry signal evoked by CaCl 2 addition, whereas it moderately reduces Ca 2+ mobilization from stores with 10% to 30% in platelet. Synta66 (10 μM) suppresses human platelet activation in plasma and whole-blood thrombus formation. Synta66 (10 μM) also inhibits murine platelet responses and thrombus formation. Synta66 (10 μM) inhibits LAD2 human mast cell line. Synta66 (10 μM) significantly inhibits FcεRI stimulated histamine and TNFα secretion, and has differential effects on FcεRI stimulated prostaglandin D2 and cytokine release in human lung mast cells (HLMCs)
A selective SOCE inhibitor that blocks CRAC current (ICRAC) without significant off-target potency or affinity.
Synta66 (S66) is a CRAC (Ca2+ release-activated Ca2+) channel inhibitor that blocks SOCE (store-operated Ca2+ entry) upon Ca2+ depletion from i
申し込み
Synta66 has been used:
as a Ca2+ release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoforms
as an ORAI1 blocker to study its effects on the entry of Ca2+ in chronic lymphocytic leukemia (CLL) B cells
as a CRAC blocker to stud
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
External Descriptors
Not available
1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
